Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Trial records in metabolic dysfunction-associated steatohepatitis

22 records bearing on metabolic dysfunction-associated steatohepatitis.

Showing 0 records on this page

Records

22 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
ESSENCESemaglutidePhase 3ReportedRandomised, double-blind, placebo-controlled1,1972025Moderate
ESSENCE-PKprogramme recordSemaglutidePhase 1ReportedPhase 1 ascending dose—2025Very low
ESSENCE-RENAL-IMPprogramme recordSemaglutidePhase 1ReportedPhase 1 ascending dose—2025Very low
ESSENCE-DDIprogramme recordSemaglutidePhase 1ReportedRandomised crossover—2025Very low
SURVO-PH2-MASHSurvodutidePhase 2ReportedRandomised, double-blind, placebo-controlled2952024Low
SYNERGY-NASHTirzepatidePhase 2ReportedRandomised, double-blind, placebo-controlled1902024Low
SURVO-PH2-MASH-PKprogramme recordSurvodutidePhase 1ReportedPhase 1 ascending dose—2024Very low
SYNERGY-NASH-REGIONAL-CNprogramme recordTirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled—2024Very low
SURVO-PH2-MASH-RENAL-IMPprogramme recordSurvodutidePhase 1ReportedPhase 1 ascending dose—2024Very low
SYNERGY-NASH-QOLprogramme recordTirzepatidePhase 2ReportedRandomised, double-blind, placebo-controlled—2024Very low
SYNERGY-NASH-BODY-COMPprogramme recordTirzepatidePhase 2ReportedRandomised, double-blind, placebo-controlled—2024Very low
TESA-NAFLD-PH2TesamorelinPhase 2ReportedRandomised, double-blind, placebo-controlled612019Low
TESA-NAFLD-PH2-PKprogramme recordTesamorelinPhase 1ReportedPhase 1 ascending dose—2019Very low
TESA-NAFLD-PH2-RENAL-IMPprogramme recordTesamorelinPhase 1ReportedPhase 1 ascending dose—2019Very low
TESA-NAFLD-PH2-HEPATIC-IMPprogramme recordTesamorelinPhase 1ReportedPhase 1 ascending dose—2019Very low
TESA-NAFLD-PH2-BODY-COMPprogramme recordTesamorelinPhase 2ReportedRandomised, double-blind, placebo-controlled—2019Very low
LIVERAGELiraglutidePhase 2ReportedRandomised, double-blind, placebo-controlled522016Low
LIVERAGE-BIOMARKERprogramme recordLiraglutidePhase 2ReportedRandomised, double-blind, placebo-controlled—2016Very low
LIVERAGE-ADHERENCEprogramme recordLiraglutidePhase 2ReportedObservational—2016Very low
LIVERAGE-OLEprogramme recordLiraglutidePhase 2ReportedSingle-arm open-label—2016Very low
LIVERAGE-ELDERLYprogramme recordLiraglutidePhase 2ReportedRandomised, double-blind, placebo-controlled—2016Very low
LIVERAGE-RENAL-IMPprogramme recordLiraglutidePhase 1ReportedPhase 1 ascending dose—2016Very low
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.